532383 Sigma-AldrichDonecopride Fumarate - Calbiochem
A cell permeable, highly potent, selective, and partial agonist of serotonin subtype 4 receptor (Ki= 10.4 nM). Also acts as a potent, mixed type, competitive inhibitor of AChE (IC₅₀ = 16 nM).
More>> A cell permeable, highly potent, selective, and partial agonist of serotonin subtype 4 receptor (Ki= 10.4 nM). Also acts as a potent, mixed type, competitive inhibitor of AChE (IC₅₀ = 16 nM). Less<<Synonyms: 5-HT4R Agonist, AChE Inhibitor, MR31147, Serotonin receptor 5-HT4R agonist
Recommended Products
Overview
Replacement Information |
---|
Key Spec Table
Empirical Formula |
---|
C₂₂H₃₃ClN₂O₂·C₄H₄O₄·xH₂O |
References | |
---|---|
References | Lecoutey, C., et al. 2014. Proc. Natl. Acad. Sci. USA 111, E3825. |
Product Information | |
---|---|
Form | Off-white powder |
Hill Formula | C₂₂H₃₃ClN₂O₂·C₄H₄O₄·xH₂O |
Chemical formula | C₂₂H₃₃ClN₂O₂·C₄H₄O₄·xH₂O |
Hygroscopic | Hygroscopic |
Reversible | Y |
Quality Level | MQ100 |
Applications |
---|
Biological Information | |
---|---|
Primary Target | 5-HT4R |
Primary Target K<sub>i</sub> | 10.4 nM |
Secondary target | AChE |
Purity | ≥95% by HPLC |
Physicochemical Information | |
---|---|
Cell permeable | Y |
Dimensions |
---|
Materials Information |
---|
Toxicological Information |
---|
Safety Information according to GHS |
---|
Safety Information |
---|
Product Usage Statements |
---|
Packaging Information | |
---|---|
Packaged under inert gas | Packaged under inert gas |
Transport Information |
---|
Supplemental Information |
---|
Specifications |
---|
Global Trade Item Number | |
---|---|
Catalogue Number | GTIN |
532383 | 0 |
Documentation
Donecopride Fumarate - Calbiochem SDS
Title |
---|
References
Reference overview |
---|
Lecoutey, C., et al. 2014. Proc. Natl. Acad. Sci. USA 111, E3825. |
Brochure
Title |
---|
Neuroscience Solutions for productive research |
Technical Info
Title |
---|
Characterization of Estrogen Receptor α Phosphorylation Sites in Breast Cancer Tissue Using the SNAP i.d® 2.0 System |
White Paper: Further considerations of antibody validation and usage. |